Purpose: Approximately two-thirds of breast cancer are estrogen-dependent cancers, which express estrogen receptor (ER)/progesterone receptor (PR). We investigated the prognostic value of ER/PR expression in human epidermal growth factor receptor 2 (HER2)-negative and low proliferative (Ki-67 ≤ 20%) breast cancer. Methods: A retrospective review was performed of 252 breast cancer data records, identified as ER/PR-positive, low Ki-67 proliferation index (≤ 20%) and HER2-negative. The data were divided into two subgroups: a strong luminal subgroup and a weak luminal subgroup, according to hormonal receptor expression status. Outcome measures included age at diagnosis, tumor size, tumor-node-metastasis (TNM) stage, ER, PR, Bcl-2, recurrent or metastatic characteristics, disease-free survival and overall survival, of each subgroup. Results: There were no statistical differences in TNM stage or tumor numbers between the two subgroups. The strong luminal subgroup was associated with a higher Bcl-2 expression (p< 0.001). The weak luminal subgroup was associated with more frequent neural invasion (p= 0.051) and lung (p= 0.031), liver (p= 0.031) and brain (p= 0.033) metastases, than the strong luminal subgroup. Disease-free survival was significantly longer in the strong luminal subgroup than weak luminal subgroup (p= 0.015). Overall survival was also significantly improved in the strong luminal subgroup relative to the weak luminal subgroup (p= 0.014). Conclusion: The weak luminal subgroup showed worse prognosis than the strong luminal subgroup, among ER/PR-positive HER2-negative low proliferative breast cancer patients. Weak ER or PR expression, can be considered a poor prognostic factor in ER/PR-positive HER2-negative low proliferative breast cancer.
INTRODUCTION
Breast cancer is the second leading cause of cancer death in women worldwide, although overall survival (OS) of breast cancer patients has been gradually increased over the last several decades, with advances in cancer therapeutics. Approximately two-thirds of breast cancer are estrogen-dependent cancers, which express estrogen receptor (ER)/ progesterone receptor (PR). It is well-established that anti-estrogen therapy, with tamoxifen or aromatase inhibitors (AIs), is effective to reduce recurrence and mortality rate of estrogen-dependent breast cancer. The National Surgical Adjuvant Breast and Bowel Project implemented the B-14 trial, the first randomized clinical trial to assess the efficacy of adjuvant tamoxifen treatment in patients with ER-positive breast cancer and negative axillary lymph nodes. At 5-year follow-up, tamoxifen treatment was found to have a highly statistically significant benefit in disease-free survival (DFS) of all ages [1, 2] . Since the release of the first results of the Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial, for adjuvant treatment of postmenopausal women with early breast cancer, AIs have widened the field of endocrine therapy in breast cancer and AIs show an enhanced antitumor effect compared to tamoxifen [3, 4] . Despite a gradual decrease in death rate from breast cancer with anti-estrogen therapy, resistance to anti-estrogen therapy often develops in some estrogen-dependent tumors [5] . Since the first appearance of tamoxifen and AIs, endocrine-resistant breast cancer remains an active area of research [6, 7] .
In our previous study, it was demonstrated that an ER/PR-decreased subgroup, among luminal B human epidermal growth factor receptor 2 (HER2)-negative breast cancer, was associated with a higher recurrence rate and shorter survival time than an ER/PR-intact subgroup [8] . The current study attempted to investigate the clinical implication of the decreased expression of ER/PR, in a more homogeneous breast cancer subgroup, identified as HER2-negative, low pro-ORIGINAL ARTICLE liferative, with a Ki-67 below 20%. Tris-buffered saline), were used as the primary antibodies for the ER and PR assays, respectively. The secondary antibody was goat anti-mouse peroxidase conjugated immunoglobulin. 3,3'-Diaminobenzidine tetrahydrochloride (DAB), was used as the chromogen. ER and PR were scored as 0, 1+, 2+, and 3+, according to staining intensity, with a description of the percentage related to the proportion of stained nuclei in 10 high power fields [9] . The intensity scores and proportion of percentages were converted into Allred scores [10] . An Allred score of 0 was defined as negative, 2 to 6 as weak positive and 7 or 8 as strong positive [11] . We defined Allred score over 6 of both ER and PR as strong positive.
METHODS
IHC for Bcl-2 and Ki-67 was performed using the avidin-biotin peroxidase complex method, with aminoethylcarbazole as the chromogen and the Vectastain ABC Elite kit (Vector Laboratories, Burlingame, USA). Bcl-2 overexpression was defined as Bcl-2 intensity above 33%. The low proliferative group were identified, based on a Ki-67 cutoff at 20%, which was described as the optimum for stratifying high-risk patients in luminal breast cancer [12] .
IHC staining for HER2/neu
Binding of the primary antibody was detected using the Dako Quick-Staining, Labelled Streptavidin-Biotin System (Dako, Carpinteria, USA), followed by DAB chromogen addition. Each slide was scored in a blinded fashion by two pathologists, according to the manufacturer's recommended criteria. Intensity scores of 0 or 1+ were designated as negative expression and 3+ was designated as a positive expression for HER2/neu. A 2+ score was considered equivocal and analyzed by silver-enhanced in situ hybridization (SISH) [9] .
SISH for HER2
HER2 SISH was performed on a Ventana Benchmark automated instrument (Ventana Medical Systems Inc., Tucson, USA), according to the manufacturer's protocols for INFORM HER2 DNA and chromosome 17 probes. Evaluation of HER2 gene amplification status was performed in a blinded manner, using the American Society of Clinical Oncology/College of American Pathologists guidelines [13] . 
Statistical methods

66
Yujin Lee, et al.
RESULTS
Among a total of 252 breast cancer patients, 174 patients (69.0%) were classified as belonging to the strong luminal subgroup and 78 patients (31.0%) to the weak luminal subgroup.
Patient characteristics
There were no statistical differences in TNM stage or age at diagnosis (for a cutoff of 50 years) between the two subgroups. Both, mean and median age at diagnosis, were higher in the weak compared to strong luminal subgroup (52.3 vs. 51.3 and 50 vs. 48.5, respectively).
The treatment modality including chemotherapy, hormone therapy, and radiotherapy did not show statistical differences between two subgroups (Table 1) .
Tumor characteristics
There were no statistical differences in the tumor number, histologic type, histologic grade, nuclear grade, lymphatic invasion, vascular invasion and Ki-67 expression, between the two subgroups. However, the strong luminal subgroup was associated with a higher Bcl-2 expression (>33%) (p < 0.001) and the weak luminal subgroup was associated with more frequent neural invasion (p = 0.051) ( Table 2 ). ER = estrogen receptor; PR = progesterone receptor; HER2 = human epidermal growth factor receptor 2; TMN = tumor-node-metastasis; AJCC = American Joint Committee on Cancer; BCS = breast-conserving surgery; SL-ND= sentinel lymph node dissection; ALND= axillary lymph node dissection. 
DFS and OS
Both DFS and OS were significantly improved in the strong luminal subgroup relative to the weak luminal subgroup (p = 0.015 and p = 0.014, respectively) ( Figure 1 ).
Multivariate analysis of prognostic factors
In a multivariate model for OS, a relationship was confirmed for the strength of ER and PR expression, age, TNM stage, and histologic grade (Table 4 ). In this model, strong luminal group remained as an 
DISCUSSION
For a patient with newly diagnosed breast cancer, the classification of the patient into either the high-or low-risk population of relapse and the need for adjuvant chemo-, radiation, anti-estrogen, or target therapy are controversial. Although node-negative breast cancer patients are considered as low-risk population for relapse, approximately up to 10% to 30% of these patients relapse within 10 years after initial therapy and the majority of recurrent breast cancer patients eventually die from the disease [14] . Accordingly, abundant clinical studies have been conducted, to identify the prognostic and predictive factors that enable clinicians to estimate the risk of relapse and the drug response of individual breast cancer patients. Risk assessment for relapse, is considered an essential factor in deciding the optimal therapeutic strategy and predicting the prognosis of breast cancer.
Over the last two decades, molecular profiling or multigene assays or IHC staining of ER, PR, HER2, Ki-67 and histologic grade, to identify at least four subtypes of breast cancer, such as luminal A, luminal B, HER2-enriched, and basal-like, have been investigated and performed, to improve the prognostication and risk stratification in breast cancer [15] . Ki-67, a nuclear marker of cell proliferation, is one of the most extensively studied markers in breast cancer [16] .
A new cutoff value of Allred score 7 was de ned for the strength of ER and PR expression in this research. High levels of ER expression (Allred scores of 7 and 8) ensured the response rate of neoadjuvant endocrine therapy for breast cancer patients in previous studies [17] .
From this perspective, we investigated the significance of this value in determining the prognosis of ER/PR positive low proliferative HER2-negative breast cancer.
The Ki-67 cutoff value, to differentiate two luminal A and B categories, has been changing over time. The 2011 Saint Gallen Consensus Meeting, defined low-risk tumors as having a Ki-67 cutoff of <14%.
In the 2013 Saint Gallen Conference, the majority of panelists voted that a threshold of ≥ 20% was indicative of high Ki-67 status. For the last several years, many investigators proposed that a 20% Ki-67 cutoff, is the best to stratify high-risk patients in luminal breast cancer [12] . In this context, the current study investigated the characteristics of low proliferative HER2-negative breast cancer patients, with a Ki-67 cutoff of 20%.
In many studies including meta-analyses, the expression of Bcl-2 was confirmed as a favorable prognostic factor for breast cancer due to its correlation with ER status [18] . Recently, Dawson et al. [19] reported that Bcl-2 is an independent parameter of a better prognosis for all types of early-stage breast cancer. In multivariable analysis, Ki-67 was also concluded as an independent prognostic indicator, in terms of both DFS and OS for breast cancer [20] . When we analyzed tumor characteristics, according to the strength of ER and PR expression, the weak luminal subgroup was associated with frequent neural invasion, low Bcl-2 expression and a relatively higher Ki-67 (14%-20%) than the strong luminal subgroup. Therefore, the weak luminal subgroup is related to worse prognostic factors relative to the strong luminal subgroup.
Regarding distant metastatic recurrences and locoregional recurrences, we observed a more frequent distant metastasis, particularly to the lung, liver and brain, in the weak luminal subgroup than the strong luminal subgroup. We also observed a survival gap between the strong and weak luminal subgroups. These findings indicate that decreased ER/PR expression, has clinical prognostic implication in the HER2-negative luminal subgroup. Meaningfully, the weak luminal subgroup in this study, also includes cases with an Allred score of 5 and 6, expressing sufficient ER/PR to respond to endocrine therapy. This is the reason we carefully presume that decreased expression of ER/PR itself, might be related to drug resistance or metastatic potency.
The study by Balduzzi et al. [21] concluded tumors presenting low ER/PR expression, had similar outcomes when compared with triple-negative breast cancer. Their result showed no clear effect on survival outcomes with the addition of endocrine therapy, for patients with ER/PR expression of 1% to 10% [21] . The poor response to hormonal therapy, can be considered as a factor in explaining the worse prognosis of the weak compared to the strong luminal subgroup. In contrast, a meta-analysis of randomized trials concluded that even weakly positive ER, substantially bene ted from tamoxifen but the proportional e ect at a much higher ER was only slightly better [22] .
Ono et al. [23] recently reported that PR expression and tumor size, were independent prognostic factors in the luminal A-like subtype and, also, the luminal A/PR-negative subtype had a higher risk of recurrence than the luminal A/PR-positive subtype. Given that the luminal A/PR-negative subtype largely overlapped with the weak luminal subgroup in our study, we carefully suggest that decreased ER/PR expression might be considered a meaningful prognostic factor in low proliferative HER2-negative breast cancer.
The weak luminal subgroup showed a worse prognosis than the strong luminal subgroup, among HER2-negative low proliferative breast cancer patients. Decreased expression of ER/PR itself, could be a clinical prognostic factor in HER2-negative low proliferative breast cancer. Current molecular classification of breast cancer represented as luminal type, is not sufficient for determining the high-risk group and additional gene analysis should be considered for the patients with relatively poor prognostic factors, like low ER/PR expression.
